Insulin-like growth factors in human breast cancer

被引:69
作者
Ellis, MJ
Jenkins, S
Hanfelt, J
Redington, ME
Taylor, M
Leek, R
Siddle, K
Harris, A
机构
[1] Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA
[2] Univ Oxford, John Radcliffe Hosp, Med Oncol Unit, Imperial Canc Res Fund, Oxford OX1 2JD, England
[3] Addenbrookes Hosp, Dept Clin Biochem, Cambridge, England
[4] Univ Cambridge, Sch Clin Med, Cambridge, England
关键词
breast cancer; insulin-like growth factors (IGFs); IGF receptors; IGF binding proteins; prognosis; chemotherapy; hormone therapy; radiation therapy;
D O I
10.1023/A:1006127621512
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IGF1 and IGF2 are circulating peptide hormones and locally-acting growth factors with both paracrine and autocrine functions. IGF1 and IGF2 signal through a common tyrosine kinase receptor, the insulin-like growth factor 1 receptor (IGF1R), and have mitogenic, cell survival, and insulin-like actions that are essential for embryogenesis, post-natal growth physiology, and breast development. The activities of IGF1 and 2 are tightly-regulated by a network of binding proteins and targeted degradation mechanisms. This complex regulatory system is disrupted in breast cancer, leading to excess IGF1R signaling. Evidence for this statement includes: a) breast cancers are infiltrated with IGF2 expressing stromal cells; b) mannose 6-phosphate/IGF2 receptor (M6P/IGF2R) is mutated in breast cancer, leading to loss of IGF2 degradation; c) IGF1R is overexpressed by malignant breast epithelial cells, and in some cases IGF1R is amplified; and d) complex changes in IGF binding protein expression occur during breast cancer progression which most likely also affect IGF1 and 2 signaling. The clinical importance of these epigenetic and genetic changes has recently been stressed by the finding that IGF1R signaling alters the apoptotic response of breast cancer cells to genotoxic stress and, in addition, IGF1R activation sensitizes cells to estrogen by inducing phosphorylation of the estrogen receptor. As a consequence of these findings, we propose that IGF analysis of breast cancer samples should shift from prognostic studies to an evaluation of IGF ligands, receptors, and binding proteins as resistance/sensitivity markers for radiation, chemotherapy, and endocrine therapy.
引用
收藏
页码:175 / 184
页数:10
相关论文
共 62 条
  • [1] THE INSULIN-LIKE GROWTH-FACTOR-I RECEPTOR GENE IS THE TARGET FOR THE 15Q26 AMPLICON IN BREAST-CANCER
    ALMEIDA, A
    MULERIS, M
    DUTRILLAUX, B
    MALFOY, B
    [J]. GENES CHROMOSOMES & CANCER, 1994, 11 (01) : 63 - 65
  • [2] BASERGA R, 1995, CANCER RES, V55, P249
  • [3] MAMMARY-CANCER IN TRANSGENIC MICE EXPRESSING INSULIN-LIKE GROWTH-FACTOR-II (IGF-II)
    BATES, P
    FISHER, R
    WARD, A
    RICHARDSON, L
    HILL, DJ
    GRAHAM, CF
    [J]. BRITISH JOURNAL OF CANCER, 1995, 72 (05) : 1189 - 1193
  • [4] BONNETERRE J, 1990, CANCER RES, V50, P6931
  • [5] INDUCTION OF THE GROWTH INHIBITOR IGF-BINDING PROTEIN-3 BY P53
    BUCKBINDER, L
    TALBOTT, R
    VELASCOMIGUEL, S
    TAKENAKA, I
    FAHA, B
    SEIZINGER, BR
    KLEY, N
    [J]. NATURE, 1995, 377 (6550) : 646 - 649
  • [6] A 2ND SIGNAL SUPPLIED BY INSULIN-LIKE GROWTH-FACTOR-II IN ONCOGENE-INDUCED TUMORIGENESIS
    CHRISTOFORI, G
    NAIK, P
    HANAHAN, D
    [J]. NATURE, 1994, 369 (6479) : 414 - 418
  • [7] Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone
    Clarke, RB
    Howell, A
    Anderson, E
    [J]. BRITISH JOURNAL OF CANCER, 1997, 75 (02) : 251 - 257
  • [8] REGULATION OF INSULIN-LIKE GROWTH-FACTOR (IGF)-BINDING PROTEIN-6 AND MANNOSE-6-PHOSPHATE/IGF-II RECEPTOR EXPRESSION IN IGF-II-OVEREXPRESSING NIH 3T3 CELLS
    CLAUSSEN, M
    BUERGISSER, D
    SCHULLER, AGP
    MATZNER, U
    BRAULKE, T
    [J]. MOLECULAR ENDOCRINOLOGY, 1995, 9 (07) : 902 - 912
  • [9] CLEMMONS RD, 1997, CYTOKINE GROWTH F R, V8, P45
  • [10] CULLEN KJ, 1991, CANCER RES, V51, P4978